Does APIXABAN Cause Product packaging quantity issue? 129 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 129 reports of Product packaging quantity issue have been filed in association with APIXABAN (ELIQUIS). This represents 0.1% of all adverse event reports for APIXABAN.
129
Reports of Product packaging quantity issue with APIXABAN
0.1%
of all APIXABAN reports
1
Deaths
14
Hospitalizations
How Dangerous Is Product packaging quantity issue From APIXABAN?
Of the 129 reports, 1 (0.8%) resulted in death, 14 (10.9%) required hospitalization, and 1 (0.8%) were considered life-threatening.
Is Product packaging quantity issue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for APIXABAN. However, 129 reports have been filed with the FAERS database.
What Other Side Effects Does APIXABAN Cause?
Death (18,501)
Cerebrovascular accident (7,237)
Atrial fibrillation (5,690)
Off label use (5,590)
Thrombosis (5,298)
Fall (5,063)
Cardiac disorder (4,917)
Haemorrhage (4,770)
Dyspnoea (4,379)
Gastrointestinal haemorrhage (4,030)
What Other Drugs Cause Product packaging quantity issue?
LEUPROLIDE (523)
ALBUTEROL (431)
BUDESONIDE\FORMOTEROL (301)
FENTANYL (286)
BUPRENORPHINE (225)
CYCLOSPORINE (206)
ESTRADIOL (201)
BIMATOPROST (177)
RIVAROXABAN (174)
EXENATIDE (154)
Which APIXABAN Alternatives Have Lower Product packaging quantity issue Risk?
APIXABAN vs APOMORPHINE
APIXABAN vs APRACLONIDINE
APIXABAN vs APREMILAST
APIXABAN vs APREPITANT
APIXABAN vs APROTININ